Analysis-Trump administration leaves Congress in dark on spending decisions
WASHINGTON (Reuters) -Around 300 students in Cleveland Heights, Ohio, may face changes to after-school tutoring and English-language proficiency instruction unless the district's $860,000 federal grant is freed up by President Donald Trump's administration in time for the new school year.
This funding is a part of more than $6 billion in school funds held up on July 1 for school programs nationwide, leaving superintendents including Cleveland Heights' Elizabeth Kirby in a budget bind. "We have not received any information about whether or not this money is coming," she said.
The lack of clarity follows a broader pattern in which the Trump administration has provided less detail on how it plans to spend taxpayer dollars, drawing criticism from some Republicans in Congress.
"Delayed budgets, missing details, and omitted spend plans make the federal budget less transparent and less accountable to the people and their elected representatives," Republican Senator Susan Collins of Maine, who chairs the Senate Appropriations Committee told Russell Vought, director of the U.S. Office of Management and Budget, at a June 25 hearing.
The OMB and the White House did not respond to a request for comment. In previous statements, the OMB said the held-up education funds are a part of an "ongoing programmatic review" due to initial findings of grant programs being "grossly misused to subsidize a radical leftwing agenda."
Budget experts say this unwillingness to share a broad range of spending details skirts funding law, complicates the budget process going forward, and breaks from precedent aimed at increasing spending transparency.
"At this point in the year, there has never been less reliable information available to either the public or Congress about actual agency spending than at any time since the modern budget process was established in 1974,' said David Taylor, a former leader of President George H.W. Bush's White House budget office and chief budget aide to Senate Majority Leader Bob Dole, who now runs the research firm Federal Budget IQ.
The U.S. Constitution gave Congress the power of the federal purse to decide how to allocate taxpayer money for the executive branch to disburse throughout its agencies.
But since lawmakers passed a full-year stopgap funding bill in March -- signed by Trump -- they have been left with questions about where the money is going because a wide swath of federal agencies across the government either failed to share spending plans required by the stopgap bill, or sent incomplete data, according to U.S. lawmakers.
'This administration has — more than any other in my time in office — refused to share basic information with this committee," said Democratic Senator Patty Murray, a 32-year veteran of the chamber and her party's top appropriator.
This standoff on federal funding powers will be tested again this week as the Senate considers the administration's $9 billion request to cancel foreign aid and public media, which could undo the funding passed on a bipartisan basis in March with a simple Republican majority.
The Republican-controlled Congress early this month narrowly passed Trump's sweeping tax-cut and spending bill, overriding some Republicans' objections about the heavy toll it was expected to take on the nation's $36.2 trillion in debt.
'NEED MORE INFORMATION'
The administration's reluctance to share detailed spending plans has placed Cabinet secretaries in the hot seat on Capitol Hill for the last several weeks, as the funding law required these details by the end of April.
'We need more information than we have gotten," Republican House of Representatives Appropriations Chair Tom Cole of Oklahoma told Defense Secretary Pete Hegseth in June, more than a month after his department's spending plan was required.
'I'm doing the best I can," FBI Director Kash Patel said at his May hearing, pointing the finger at other parts of the administration when hounded about the lack of spending details.
'We have a lot of irons in the fire ... as we try to build up staff,' explained Interior Secretary Doug Burgum when pressed by Democratic Senator Jeff Merkley of Oregon about the lack of clarity on conservation projects.
Even the agency plans that were submitted had notable gaps. There were 530 asterisks in the Health and Human Services Department's plan where specific funding amounts for programs should have been listed, according to Murray and Representative Rosa DeLauro, the top House appropriations Democrat.
"The fact that appropriators are discussing these issues in open hearings means that multiple attempts to get this information behind the scenes has failed," said Joe Carlile, a former Democratic budget official.
TRANSPARENCY DIVIDE
Trump's focus on slashing the federal government also has made his administration less concerned about congressional queries, said Cerin Lindgrensavage, counsel at Protect Democracy, a group which is suing the administration over removal of online spending details.
"Usually, administration officials would be wary of angering the appropriations committee for the same reason it's a bad idea to bite the hand that feeds you, but now, Congress is negotiating against an executive branch that seems happy to cut more spending," Lindgrensavage said.
Veterans Affairs Secretary Doug Collins cited White House budget office guidance and a 1983 Supreme Court ruling over congressional restraints on emergency powers to defend how his department notified Congress to "reprogram" money away from initiatives the administration deemed wasteful.
Congressional leaders tasked with overseeing VA funding demanded the department request approval to redirect money.
"The way this secretary, and this administration, has interacted with Congress on moving hundreds of millions of dollars from one account to the next is unprecedented," said Democratic Representative Debbie Wasserman Schultz of Florida.
The panel's Republican leader, Representative John Carter of Texas, backed Schultz up: "I've been on this committee for 20 years ... and we are not going to change it now."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio